Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Standard Lithium Ltd (SLI) Price & Performance

CVS Health CorpTrade
Standard Lithium LtdTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Standard Lithium Ltd — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while Standard Lithium Ltd trades at $1.62 (market cap $398.07M). The key difference: CVS Health Corp is far larger — about 282.1× Standard Lithium Ltd's market cap, and CVS Health Corp pays a 3.03% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Standard Lithium Ltd for 23 Days on average.

CVSSLI
Market Cap
$112.29B$398.07M
Volume
7,763,6761,564,155
Sector
HealthBasic Materials
52-Week High
$110.60$5.65
52-Week Low
$70.08$1.61
Typical Hold Time
83 Days23 Days
Enterprise Value
$174.64B$260.98M
Dividend Yield
3.03%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.

The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.

Standard Lithium Ltd

Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported no revenue in 2025 and negative net income of -$48.40M, though recent quarters show improving EPS trends with two consecutive beats. Key developments include progress toward a final investment decision for the South West Arkansas lithium project by end-2026 and new customer offtake agreements.

The stock presents high-risk, high-reward potential with 100% analyst buy ratings and a $3.83 consensus price target offering 132% upside. However, significant execution risks remain as the company transitions to commercial production, with negative cash flow from operations and substantial capital requirements ahead.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS

No sentiment data available yet.

SLI
100% Buy0% Sell
Avg holding period · 23 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Standard Lithium Ltd

Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.

Read more on SLI →